Discovery of SARS-CoV-2 Nsp14 and Nsp16 Methyltransferase Inhibitors by High-Throughput Virtual Screening

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses mRNA capping to evade the human immune system. The cap formation is performed by the SARS-CoV-2 mRNA cap methyltransferases (MTases) nsp14 and nsp16, which are emerging targets for the development of broad-spectrum antiviral agent...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmaceuticals (Basel, Switzerland) Jg. 14; H. 12; S. 1243
Hauptverfasser:	Bobrovs, Raitis, Kanepe, Iveta, Narvaiss, Nauris, Patetko, Liene, Kalnins, Gints, Sisovs, Mihails, Bula, Anna L., Grinberga, Solveiga, Boroduskis, Martins, Ramata-Stunda, Anna, Rostoks, Nils, Jirgensons, Aigars, Tars, Kaspars, Jaudzems, Kristaps
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland MDPI AG 30.11.2021 MDPI
Schlagworte:	Amino acids antiviral drugs Binding sites Coronaviruses COVID-19 Enzymes Epidemics high-throughput virtual screening Hydrogen bonds Immune system Ligands Middle East respiratory syndrome MTase inhibitors nsp14 nsp16 Respiratory diseases SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 antiviral drugs SARS-CoV-2 nsp14 high-throughput virtual screening MTase inhibitors nsp16
ISSN:	1424-8247, 1424-8247
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!